In the dog-eat-dog world of federal deficit reduction, there seems to be one health-related spending cut with broad bi-partisan support: require drug companies to give the federal government “a better deal on medications for low-income people on Medicare.”
In the dog-eat-dog world of federal deficit reduction, there seems to be one health-related spending cut with broad bi-partisan support: require drug companies to give the federal government “a better deal on medications for low-income people on Medicare.” Nearly 70% of respondents back this strategy, according to a survey sponsored by the Kaiser Family Foundation (KFF), the Robert Wood Johnson Foundation and the Harvard School of Public Health. That’s far more than the mere 32% who want to raise Medicare premiums or the 26% who support a higher Medicare eligibility age (67, up from 65 years).
Most notable is the surprisingly strong bipartisan support for this hit on pharma: 61% of Republicans “strongly favor” this action, as do 77% of Democrats, according to this January poll. Congressional Democrats have been pressing hard to require pharma companies to pay rebates on drugs provided to Medicare “dual eligible” beneficiaries who qualify for assistance from state Medicaid programs and previously received prescription drugs through state plans that collect rebates.
Meanwhile, most of the 1347 people surveyed want to keep funds flowing to other government health-related programs, such as veteran’s health, anti-terrorist preparations, research to find new cures and treatments, and actions to prevent chronic illnesses and the spread of infectious diseases. Less than half (47%) back government funding of “programs to ensure the safety and effectiveness of prescription drugs,” reflecting less enthusiasm for FDA operations.
The biggest surprise for the pollsters was the relatively strong backing – from both Democrats and Republicans – for state governments to establish health insurance exchanges this year. More than half (55%) of those answering the survey list creating exchanges, or “marketplaces,” as a top priority.
Although most respondents– particularly Republicans – want quick action to tackle the federal budget deficit, there’s not much consensus on where the axe should fall. No surprise that Democrats prefer to raise taxes, while Republicans want to reduce federal spending. The most popular revenue-raiser is to hike taxes for people making more than $400,000 a year. But the majority opposes reductions in spending on education, Medicare, and social security – and economists say that any serious budget cutting has to hit those programs.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.